Avicanna Secures Patent for Innovative Topical Technology
Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) has received a significant boost with the issuance of Patent No. US 20230025693A1 by the United States Patent and Trademark Office (“USPTO”). This patent covers Avicanna's groundbreaking deep-penetrating topical cannabinoid composition, specifically designed to treat musculoskeletal inflammation and pain.
Significance of the New Patent
“We are thrilled about the issuance of another USPTO patent, particularly for our transdermal topical technology, which has been a crucial focus of our research and development (R&D) and clinical initiatives,” said Aras Azadian, CEO of Avicanna. This innovative technology is the result of years of dedicated research, development, and clinical trials, which included AI-guided prediction modeling and real-world evidence.
With this patent, Avicanna anticipates key advancements as it integrates these technologies into its expanding product pipeline, especially for effectively addressing challenges related to musculoskeletal pain and inflammation.
Advantages of Topical Formulations
While there are numerous medications available to relieve pain, they often come with undesirable side effects. Avicanna's topical formulations offer a potential advantage by delivering active ingredients directly into the deeper layers of tissue, enhancing their effectiveness while minimizing gastrointestinal, central nervous system, and cardiovascular side effects.
Results Backed by Evidence
Extensive real-world evidence supports the efficacy of this technology. In a recent study involving seventy-one patients experiencing symptoms related to musculoskeletal pain and inflammation, participants completed two standardized symptom questionnaires. After one month of using the RHO Phyto CBG Transdermal Gel, which contains 2% cannabidiol and 1% Cannabigerol, many reported significant improvements in their quality of life and symptom management.
Overview of Avicanna’s Advanced Technology
The technology behind Avicanna's transdermal products enhances the absorption of cannabinoids through the skin. This innovative method utilizes a specially designed nano- and micro-emulsion system, stabilized within a gel matrix that includes effective penetration enhancers. The patented water-based gel combines Avicanna's deep tissue technology with synergistic terpenes and natural excipients.
Avicanna’s Commitment to Excellence
Avicanna is committed to the development and commercialization of cannabinoid-based products, supported by extensive R&D capabilities. The company has launched over thirty proprietary, evidence-based products, reinforcing its vision to lead in the global medical and pharmaceutical markets.
Exploring Avicanna's Product Range
Avicanna's medical cannabis formulary, RHO Phyto™, is recognized for its wide variety of proprietary products, including oral, sublingual, topical, and transdermal delivery systems with different cannabinoid concentrations. RHO Phyto has emerged as a leading medical brand, expanding its presence in international markets while maintaining a strong foothold in Canada.
Innovative Solutions for Health
The company also provides a sophisticated medical cannabis care platform called MyMedi.ca. This platform is designed to assist patients and enhance their health journeys. MyMedi.ca operates under Northern Green Canada Inc. and offers a diverse range of products along with bilingual pharmacist-led support programs, catering to various patient needs.
Avicanna’s Future Prospects
Additionally, Avicanna’s pharmaceutical product line includes Trunerox™, which has recently been approved as an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. This approval underscores Avicanna's commitment to addressing unmet medical needs in neurology and chronic pain through scientific innovation.
Final Thoughts
As Avicanna Inc. continues to navigate the evolving landscape of cannabinoid-based therapies, its newly acquired patent positions the company advantageously. By leveraging its scientific expertise and established business foundations, Avicanna is well-prepared for significant advancements in the pharmaceutical sector of cannabinoid products.
Frequently Asked Questions
What is the new patent issued to Avicanna about?
The patent covers Avicanna’s deep penetrating topical cannabinoid composition aimed at treating musculoskeletal inflammation and pain.
How does Avicanna's topical technology work?
The technology is designed to enhance the transdermal delivery of cannabinoids, allowing for better penetration and efficacy while reducing systemic side effects.
What are the reported results from Avicanna’s clinical studies?
In clinical studies, participants using RHO Phyto CBG Transdermal Gel reported significant improvements in symptoms and quality of life related to musculoskeletal issues.
Where can Avicanna’s products be accessed?
Avicanna's RHO Phyto products are available nationwide in Canada and are gradually expanding into international markets.
What is Avicanna’s commitment to innovation?
Avicanna is committed to developing cannabinoid-based products backed by strong research and clinical evidence, addressing various medical needs across different specialties.
